Homepage Top Section1

Durvalumab reduced the risk of death by 32% in comparison to standard of care in the late-stage trial. In the durvalumab arm, the median time to death or

Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year

The approval of Hulio is based on adoption of positive opinion by the Committee for Medicinal Products for Human Use (CHMP). The CHMP determined that development program, including

The CLR 131 is an investigational radioiodinated PDC therapy, which exploits the tumor-targeting properties of the firm’s phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to

Adapt Pharma is a privately-held company committed to expanding affordable access to Narcan (naloxone HCI) nasal spray and to progressing treatment options in the field of addiction. The

In the trial, Bevespi Aerosphere, a rival COPD treatment to GSK’s product, showed non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1) but and failed

As per the research published in Nature Communications, the scientists at the University of Cambridge discovered that a protein called BCL11A is found in high amounts in lung